Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nephros (NEPH) Current Deferred Revenue (2016 - 2017)

Nephros has reported Current Deferred Revenue over the past 8 years, most recently at $70000.0 for Q4 2017.

  • Quarterly results put Current Deferred Revenue at $70000.0 for Q4 2017, down 69.16% from a year ago — trailing twelve months through Dec 2017 was $70000.0 (down 69.16% YoY), and the annual figure for FY2017 was $70000.0, down 69.16%.
  • Current Deferred Revenue for Q4 2017 was $70000.0 at Nephros, roughly flat from $70000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for NEPH hit a ceiling of $708000.0 in Q1 2013 and a floor of $70000.0 in Q4 2014.
  • Median Current Deferred Revenue over the past 5 years was $148500.0 (2014), compared with a mean of $270550.0.
  • Biggest five-year swings in Current Deferred Revenue: crashed 90.04% in 2014 and later soared 447.14% in 2016.
  • Nephros' Current Deferred Revenue stood at $703000.0 in 2013, then crashed by 90.04% to $70000.0 in 2014, then changed by 0.0% to $70000.0 in 2015, then soared by 224.29% to $227000.0 in 2016, then plummeted by 69.16% to $70000.0 in 2017.
  • The last three reported values for Current Deferred Revenue were $70000.0 (Q4 2017), $70000.0 (Q3 2017), and $70000.0 (Q2 2017) per Business Quant data.